Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Applying to The Angeles Clinic and Research Institute - West Los Angeles Office · Los Angeles, California
Answer a few short questions to share with the research team.